GSK/Vir’s Xevudy Begins EU Review For COVID-19
EMA Issues Scientific Opinion On Molnupiravir
Things are happening very quickly on the COVID-19 front, with sotrovimab, molnupiravir, Paxlovid and Novaxovid all under EU review for marketing authorization or emergency use, and EMA decisions expected on boosters and the use of vaccines in younger age groups.
